Hui Zhang
机构：Shihezi University, Fujian Medical University, United States Food and Drug Administration, Center for Drug Evaluation and Research, Shanghai Medical College of Fudan University, Shanghai University of Engineering Science, Beijing Normal University, Jiangsu Academy of Agricultural Sciences, Fudan University Shanghai Cancer Center, Shanxi Provincial Cancer Hospital, Taiyuan Heavy Industry (China), Fujian Provincial Hospital, Shanghai Clinical Research Center, Wuhan University of Science and Technology
发表论文 152 篇 · 总被引 4266 次 · h-index 24
代表论文
- Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer (2025 · Cell Reports Medicine · 被引 17)
- Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer (2025 · Journal of Clinical Oncology · 被引 13)
- US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2–Low or Human Epidermal Growth Factor Receptor 2–Ultralow Breast Cancer (2025 · Journal of Clinical Oncology · 被引 12)
- Predicting the environmental fate of biodegradable mulch films: A machine learning approach for sustainable agriculture (2025 · Journal of Hazardous Materials · 被引 10)
- Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study (2025 · Clinical Cancer Research · 被引 5)
- Comprehensive dissection of rectal cancer organoids in responses to chemoradiation (2025 · Cell Reports Medicine · 被引 4)